114 related articles for article (PubMed ID: 12676891)
1. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys.
Ramakrishnan R; Cheung WK; Farrell F; Joffee L; Jusko WJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):324-31. PubMed ID: 12676891
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.
Ramakrishnan R; Cheung WK; Wacholtz MC; Minton N; Jusko WJ
J Clin Pharmacol; 2004 Sep; 44(9):991-1002. PubMed ID: 15317827
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.
Woo S; Krzyzanski W; Jusko WJ
J Pharmacol Exp Ther; 2006 Dec; 319(3):1297-306. PubMed ID: 16973883
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.
Krzyzanski W; Jusko WJ; Wacholtz MC; Minton N; Cheung WK
Eur J Pharm Sci; 2005 Nov; 26(3-4):295-306. PubMed ID: 16102948
[TBL] [Abstract][Full Text] [Related]
5. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin.
Woo S; Jusko WJ
Drug Metab Dispos; 2007 Sep; 35(9):1672-8. PubMed ID: 17576810
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia.
Chanu P; Gieschke R; Charoin JE; Pannier A; Reigner B
J Clin Pharmacol; 2010 May; 50(5):507-20. PubMed ID: 20179322
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes.
Varlet-Marie E; Gaudard A; Audran M; Gomeni R; Bressolle F
Int J Sports Med; 2003 May; 24(4):252-7. PubMed ID: 12784166
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys.
Sun YN; Lee HJ; Almon RR; Jusko WJ
J Pharmacol Exp Ther; 1999 Jun; 289(3):1523-32. PubMed ID: 10336548
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats.
Yoon WH; Park SJ; Kim IC; Lee MG
Res Commun Mol Pathol Pharmacol; 1997 May; 96(2):227-40. PubMed ID: 9226757
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses.
Souillard A; Audran M; Bressolle F; Jaussaud P; Gareau R
Biopharm Drug Dispos; 1996 Dec; 17(9):805-15. PubMed ID: 8968532
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of lyophilized recombinant human erythropoietin-alpha following single-dose subcutaneous administration in premature newborns.
Melo AM; Costa MT; Porta V; Vaz FA
J Matern Fetal Neonatal Med; 2005 Jan; 17(1):55-8. PubMed ID: 15804788
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of several subcutaneous doses of erythropoietin: potential implications for blood transfusion.
Sans T; Joven J; Vilella E; Masdeu G; Farrè M
Clin Exp Pharmacol Physiol; 2000 Mar; 27(3):179-84. PubMed ID: 10744344
[TBL] [Abstract][Full Text] [Related]
14. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys.
Mager DE; Neuteboom B; Efthymiopoulos C; Munafo A; Jusko WJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):262-70. PubMed ID: 12660309
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.
Zia-Amirhosseini P; Minthorn E; Benincosa LJ; Hart TK; Hottenstein CS; Tobia LA; Davis CB
J Pharmacol Exp Ther; 1999 Dec; 291(3):1060-7. PubMed ID: 10565825
[TBL] [Abstract][Full Text] [Related]
16. [Erythropoietin administration to preterm infants: comparison between subcutaneous and intravenous route].
Rigourd V; Kieffer F; Dommergues MA; Ayachi A; Assaf Z; Mohamed I; Voyer M; Magny JF
Arch Pediatr; 2004 Apr; 11(4):319-26. PubMed ID: 15051090
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.
Ait-Oudhia S; Scherrmann JM; Krzyzanski W
J Pharmacol Exp Ther; 2010 Sep; 334(3):897-910. PubMed ID: 20501635
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of subcutaneous injection and intravenous infusion of recombinant human interleukin-12 and recombinant human interleukin-12 combined with hepatitis B surface antigen in cynomolgus monkeys.
Li R; Deng F; Fu Y; Zhang Y; Wan H; Zhou D; Gu J; Xu J
Pharmacology; 2010; 85(6):319-27. PubMed ID: 20516733
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers.
Woo S; Krzyzanski W; Duliege AM; Stead RB; Jusko WJ
J Clin Pharmacol; 2008 Jan; 48(1):43-52. PubMed ID: 18025524
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
Olsson-Gisleskog P; Jacqmin P; Perez-Ruixo JJ
Clin Pharmacokinet; 2007; 46(2):159-73. PubMed ID: 17253886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
